<DOC>
	<DOCNO>NCT00015626</DOCNO>
	<brief_summary>The goal study aggressively treat insulin resistance clinical manifestation first appear childhood , prevent subsequent progression towards impair glucose tolerance type-2 diabetes . In process clinical trial , learn early manifestation insulin resistance , treatment , relationship obesity type-2 diabetes parallel in-vivo in-vitro study .</brief_summary>
	<brief_title>A Clinical Trial Prevent Complications Insulin Resistance ( Including Type-2 Diabetes )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Inclusion criterion : 1 . Obese patient ( wt &gt; 95th percentile age , adult increase BMI &gt; 27 ) great 5 year age 2 . And/or presence complication insulin resistance acanthosis nigricans , dyslipidemia , elevate blood pressure , hyperandrogenism 3 . Siblings parent patient insulin resistance . Siblings parent include case document insulin resistance index subject . Insulin resistance document OGTT and/or IVGTT . 4 . Family history type II diabetes . 1 . Critically ill patient , patient congestive heart failure , renal liver insufficiency 2 . Inability give consent . 3 . History poor compliance physician 's recommendation</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
</DOC>